Document is current

Article History

Accepted: 15 February 2021

First Online: 5 March 2021

Declarations

:

: No sources of funding were used for the preparation of this article.

: Juan S. Lasa receives consulting and lecture fees from Sanofi-Aventis and Abbvie. Pablo A. Olivera receives consulting fees from Abbvie, Takeda, and Janssen and lecture fees from Takeda and Janssen. Stefanos Bonovas has no conflicts of interest that are directly relevant to the content of this article. Silvio Danese receives speaking, consultancy, or advisory board member fees from Abbvie, Ferring, Hospira, Johnson and Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, and Boehringer-Ingelheim. Laurent Peyrin-Biroulet receives honoraria from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, and Amgen, grants from Abbvie, MSD, and Takeda, and stock options from CT-SCOUT.

: Not applicable.

: Not applicable.

: Not applicable.

: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

: Not applicable.

: JL: bibliographic search; inclusion and exclusion of studies for systematic review and meta-analysis; quality assessment of included studies; meta-analysis and statistical analysis; draft elaboration. PO: bibliographic search; inclusion and exclusion of studies for systematic review and meta-analysis; draft elaboration. SB: quality assessment of included studies; meta-analysis and statistical analysis; critical review of draft. SD: quality assessment of included studies; critical review of draft; LPB: study design and conception; draft elaboration and critical review of draft. All authors read and approved the final version.